The metabolic mechanism of growth inhibition by co-culture of Bacteroides xylanisolvens Y-11 and Bifidobacterium longum y37
Author:
Tian Lei123, Luo Dongmei2, Li Rui2, Jiao Pengrui2, Zhou Zhiwei2, Marks Robert S.3, Sun Qun2
Affiliation:
1. 1 College of Food and Biological Engineering , Xihua University; Food Microbiology Key Laboratory of Sichuan Province , Chengdu, 610039 , PR China . 2. 2 Key Laboratory of Bio-resources and Eco-environment, the Ministry of the Education , College of Life Sciences, Sichuan University , Chengdu, Sichuan 610064 , P. R. China . 3. 3 Avram and Stella Goldstein-Goren, Department of Biotechnology Engineering, Faculty of Engineering Sciences , Ben Gurion University of the Negev , Beer-Sheva 84105 , Israel .
Abstract
Abstract
Bacteroides xylanisolvens Y-11 and Bifidobacterium longum y37 isolated from human gut were found to inhibit each other's growth after co-culturing in previous studies. To further reveal the potential mechanism of mutual inhibition between them, ultra performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) was used to investigate the metabolic changes of the strains after monoculture and co-culture, and the key differential metabolites were subject to the validation. The results showed that the types and amounts of metabolites were significantly changed during co-culture, with hydrocarbons and their derivatives, organic acids and esters being the main differential metabolites, which posed a greater influence on the metabolism of B. xylanisolvens Y-11 than on B. longumy y37. Further studies suggest that cycloserine and succinic acid may be the main metabolites that inhibit the growth of both strains, and the decrease of pH may be the main reason for succinic acid to inhibit the growth of the two strains. Moreover, B. longum y37 played a dominant role in the co-culture and its metabolites influenced the growth of B. xylanisolvens Y-11 to a greater extent. This study provides a new perspective for further understanding of the interaction between intestinal microbes and the influence of intestinal microecology on the occurrence and development of diseases.
Publisher
Walter de Gruyter GmbH
Subject
Genetics,Molecular Biology,Biomedical Engineering,Molecular Medicine,Food Science,Biotechnology
Reference33 articles.
1. AKATSU, H., IWABUCHI, N., XIAO, J.-Z., MATSUYAMA, Z., KURIHARA, R., OKUDA, K., YAMAMOTO, T. & MARUYAMA, M. 2012. Clinical Effects of Probiotic Bifidobacterium longum BB536 on Immune Function and Intestinal Microbiota in Elderly Patients Receiving Enteral Tube Feeding. JPEN. Journal of parenteral and enteral nutrition, 37. 2. ANDRADE, S. & BORGES, N. 2009. Effect of fermented milk containing Lactobacillus acidophilus and Bifidobacterium longum on plasma lipids of women with normal or moderately elevated cholesterol. The Journal of dairy research, 76, 469-74. 3. BERTRAND, S., BOHNI, N., SCHNEE, S., SCHUMPP, O., GINDRO, K. & WOLFENDER, J.-L. 2014. Metabolite induction via microorganism co-culture: A potential way to enhance chemical diversity for drug discovery. Biotechnology advances, 32, 1180–1204. 4. BO, C., SUN, L., ZENG, G., SHEN, Z., WANG, K., YIN, L., XU, F., WANG, P., DING, Y., NIE, Q., WU, Q., ZHANG, Z., XIA, J., LIN, J., LUO, Y., CAI, J., KRAUSZ, K., ZHENG, R., XUE, Y. & JIANG, C. 2022. Gut bacteria alleviate smoking-related NASH by degrading gut nicotine. Nature, 610, 562-568. 5. BORDONI, A., AMARETTI, A., LEONARDI, A., BOSCHETTI, E., DANESI, F., MATTEUZZI, D., RONCAGLIA, L., RAIMONDI, S. & ROSSI, M. 2013. Cholesterol-lowering probiotics: In vitro selection and in vivo testing of bifidobacteria. Applied microbiology and biotechnology, 97.
|
|